ArticleBMC bioinformatics2025
A novel weighted pseudo-labeling framework based on matrix factorization for adverse drug reaction prediction.
Article in BMC bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Machine Learning Model Predicts Clinical Adverse Events of Small Molecule Kinase Inhibitors in Cancer Patients Using On-/Off-Target Engagement and Tissue Selectivity.Clinical pharmacology and therapeutics · 2026Article
- Artificial Intelligence for Drug Safety Across the Lifecycle and Decision Type: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Heterogeneous graph neural network-based prediction of immune-related adverse events.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Adverse drug reactions (ADRs) are among the global public health events that seriously endanger human life and cause high economic burdens. Therefore, predicting the possibility of their occurrence and taking early and effective response measures is of great significance. Constructing a correlation matrix between drugs and their adverse reactions, followed by effective correlation data mining, is one of the current strategies to predict ADRs using accessible public data. Since the number of known ADRs in real-world data is far less than the number of their unknown counterparts, the drug-ADR association matrix is very sparse, which greatly affects the classification performance of machine learning methods. To effectively address the problem of sparsity, we proposed a novel weighted pseudo-labeling framework that mines potential unknown drug-ADR pairs by integrating multiple weighted matrix factorization (MF) models and treating them as pseudo-labeled drug-ADR pairs. Pseudo-labeled data is added to the training set, and the MF model is fine-tuned to improve the classification performance. To prevent overfitting to easily found pseudo-labels and improve the quality of pseudo-labels, a novel weighting approach for pseudo-labels was adopted. This paper reproduces the baselines under the same experimental conditions to evaluate the performance of the proposed method on sparse data from the Side Effect Resource (SIDER) database. Experimental results showed that our method outperformed other baselines in the Area Under Precision-Recall and F1-scores and still maintained the best performance in sparser scenarios. Furthermore, we conducted a case study, and the results showed that our proposed framework efficiently predicted ADRs in the real world.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.